CClinicalTrials.gg
CompletedNCT06763705Updated Jun 8, 2026

Comparison of Safety and Efficacy for Different Sedation Regimens During Colonoscopy

A Phase 4 interventional study of Midazolam and Propofol in Deep Sedations, Conscious Sedation and Colonoscopy, sponsored by Qassim Health Cluster. Completed at 1 site in Saudi Arabia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Qassim Health Cluster · Phase 4, Interventional, and Supportive care

Phase
Phase 4
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a randomized, double-blinded, prospective study which will be conducted at the Department of Gastroenterology, King Saud Hospital, Unaizah, Qassim, Saudi Arabia. This study aims to compare safety and efficacy of different types of sedation medications for elective colonoscopy. Colonoscopy is a procedure to examine and visualize the colon by a fiberoptic tube called colonoscope. Sedation helps one to relax to avoid feel any discomfort or pain during the procedure.

Read the detailed description

The study will involve 157 patients who meet the inclusion criteria and are scheduled for elective colonoscopy. Sample size is calculated by ANOVA F test. Participants will be randomly assigned into three groups using computer-based randomization. Group I will receive intravenous midazolam + fentanyl, Group II will receive propofol only, and Group III will receive fentanyl + propofol. Dosages will be titrated as needed during the procedure, with sedation administered by trained nurses/doctors under the supervision of an anesthesiologist to ensure patient safety. Experienced endoscopists will perform the procedures, and all participants will undergo a pre-procedure evaluation, including medical history, physical examination, and assessment of allergies, comorbidities, and ASA classification. Data on patient demographics, procedure details, and sedative dosages will be collected, alongside monitoring of vital signs, oxygen saturation, and blood pressure before, during, and after the procedure.

The primary outcomes for the study include the degree of sedation, onset of sedation, patient satisfaction, and procedure completion rate. The degree of sedation will be assessed using the Observer's Assessment of Alertness/Sedation (OAA/S) scale, while the onset of sedation will be defined as the time it takes for the patient to show drowsiness and reduced responsiveness. Secondary outcomes include adverse events, recovery time, and endoscopist satisfaction. Adverse events, such as hypotension, tachycardia, bradycardia, and hypoxia, will be recorded using pre-defined criteria for each. Recovery will be assessed every 10 minutes post-procedure using the Aldrete score, with a score of 10 indicating full recovery, after which patients can be discharged. Both patient and endoscopist satisfaction will be measured on a scale of 0 to 5 using Likert scale. This comprehensive approach aims to determine the efficacy, safety, and patient/endoscopist experience associated with the three sedative regimens during colonoscopy

02

Conditions studied

  • Deep Sedations
  • Conscious Sedation
  • Colonoscopy

Keywords

  • colonoscopy
03

In context

Lead sponsor

Qassim Health Cluster is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18-60 years
  • Both Genders
  • Indication of colonoscopy procedure without advanced intervention
  • American Society of Anesthesiologists (ASA) physical status I or II
  • Competent to give informed consent

Exclusion criteria

  • Personal history of allergic reaction or other contra-indications to midazolam, propofol or fentanyl
  • Age below 18 or above 60 years
  • Chronic use of benzodiazepines
  • ASA physical status III or above
  • Pregnancy
  • History of smoking or alcohol abuse
  • Body mass index > 35 kg/m2
  • History of airway obstruction or difficult intubation
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    Midazolam + Fentanyl

    Midazolam AND Fentanyl Before start of colonoscopy procedure patient will be sedated with these drugs in this group. Doses: Midazolam: Initial dose 0.5-1 mg. Additional doses: 1 mg every 2-3 min depending sedation level, maximum dose: 6 mg. till completion of the colonoscopy procedure Fentanyl Initial dose: 12.5-75 μg Additional doses: 12.5-50 μg every 2-3 minutes. Maximum dose: 100 ug

    Drug: Midazolam · Drug: Fentanyl

  • Experimental
    Propofol

    Propofol Before start of colonoscopy procedure patient will be sedated with propofol in this group. Dose:induction dose of 20-50 mg followed by intermittent boluses of 10-20 mg according to the patient response. Maximum total dose of 200 mg. Till completion of the colonoscopy

    Drug: Propofol

  • Experimental
    Propofol +Fentanyl

    Propofol AND Fentanyl Before start of colonoscopy procedure patient will be sedated with these drugs in this group. Doses: Propofol: Induction dose of 20-50 mg followed by intermittent boluses of 10-20 mg according to the patient response. maximum total dose of 200 mg. Till completion of the colonoscopy procedure. Fentanyl Initial dose: 12.5-75 μg Additional doses: 12.5-50 μg every 2-3 minutes. Maximum dose: 100 ug. Till completion of the colonoscopy procedure

    Drug: Propofol · Drug: Fentanyl

Interventions

  • DrugMidazolam

    It will not be used alone but in combination with Fentanyl in the Midazolam + Fentanyl group.

  • DrugPropofol

    It will used alone in Propofol group and in combination with Fentanyl in the Propofol + Fentanyl group.

  • DrugFentanyl

    Fentanyl will not be used in isolation but will be used in combination with either Midazolam or Propofol in Midazolam + Fentanyl group and Propofol + Fentanyl group, respectively.

06

What researchers measure

Primary outcomes

  1. Degree of sedation

    The degree of sedation shows the depth of sedation. It will be measured by the Observer's assessment of alertness/sedation scale with a minimum and maximum value of 1 and 5 reflecting depth of sedation. Where score 1 means deeply sedated while score 5 means fully awake. Higher scores means not enough sedation.

    Time frame: every 3 minutes till the end of procedure

  2. Onset of sedation

    Onset of sedation means how rapidly patient is sedated after giving the sedative medication. if after 20 minutes, patient not sedated then it will be considered failed to sedate.

    Time frame: It will be measured every 1 minute till 20 minutes.

  3. Adverse events and complication

    Adverse events are any unintended or undesirable clinical occurrences that arise during or after a medical procedure, treatment, or intervention. These events may be related to the procedure itself, the medications administered. These may include hypotension, bradycardia, tachycardia, hypoxia, oversedation leading to respiratory suppression

    Time frame: Monitored continuously during procedure and post procedure for 2 hours and then up to 48 hours after discharge on telephone

Secondary outcomes

  1. Patient's satisfaction with the procedure

    It reflects patient's overall satisfaction about the colonoscopy procedure under given sedation. It will be assessed on Likert scale with minimum and maximum values of 1 to 5. On the Linkert scale 5 is maximum satisfaction and 1 is the least.

    Time frame: 2 hours from the start of the procedure.

  2. procedure completion rate

    The colonoscopy procedure will be considered successful if the endoscopist examines the colon from the rectum to the cecum. it will be done at 1 hour.The procedure completion rate, representing the percentage of successful procedures, will be calculated six months after collecting all data from the study.

    Time frame: Decision for procedure completion successfully or not will be at 1 hour. Procedure completion rate at 6 months

07

Study locations

1 site
  • King Saud Hospital
    Unaizah, Al-Qassim Region 56437, Saudi Arabia
08

References and documents

Study documents

  • Study protocol · Jan 6, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — IPD data will not be shared

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06763705
Lead sponsor
Qassim Health Cluster
Responsible party
Mohammed Saud Alsulaimi (Consultant gastroenterology, Qassim Health Cluster) — Principal investigator
First posted
Jan 8, 2025
Start date
Jun 15, 2025
Primary completion
Dec 14, 2025
Completion
Dec 14, 2025
Last update
Jun 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion